TY - JOUR
T1 - Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis
T2 - A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
AU - Gooderham, Melinda J.
AU - Pink, Andrew E.
AU - Simpson, Eric L.
AU - Silverberg, Jonathan I.
AU - Güler, Erman
AU - Watkins, Melissa
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/9
Y1 - 2023/9
N2 - Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg once daily is recommended as a starting and maintenance dose. This review summarizes the efficacy and safety of abrocitinib 100 mg once daily for patients with moderate-to-severe AD based on data from the pivotal phase 3 studies of the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) clinical program, JADE MONO-1 (NCT03349060), JADE MONO-2 (NCT03575871), JADE COMPARE (NCT03720470), JADE TEEN (NCT03796676), and JADE REGIMEN (NCT03627767). Preliminary long-term efficacy and safety data are also summarized from the long-term extension study JADE EXTEND (NCT03422822). Expert opinion on use of abrocitinib 100 mg once daily in clinical practice is provided. In addition to efficacy, the decision to use abrocitinib for the treatment of AD should allow for individual patient factors such as age, comorbidities, previous therapy, quality of life, and treatment tolerability, and involve shared decision-making between the patient and clinician.
AB - Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg once daily is recommended as a starting and maintenance dose. This review summarizes the efficacy and safety of abrocitinib 100 mg once daily for patients with moderate-to-severe AD based on data from the pivotal phase 3 studies of the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) clinical program, JADE MONO-1 (NCT03349060), JADE MONO-2 (NCT03575871), JADE COMPARE (NCT03720470), JADE TEEN (NCT03796676), and JADE REGIMEN (NCT03627767). Preliminary long-term efficacy and safety data are also summarized from the long-term extension study JADE EXTEND (NCT03422822). Expert opinion on use of abrocitinib 100 mg once daily in clinical practice is provided. In addition to efficacy, the decision to use abrocitinib for the treatment of AD should allow for individual patient factors such as age, comorbidities, previous therapy, quality of life, and treatment tolerability, and involve shared decision-making between the patient and clinician.
KW - Abrocitinib
KW - Clinical practice
KW - Flexible dosing
KW - JAK1-selective inhibitor
KW - Moderate-to-severe atopic dermatitis
KW - Oral systemic therapy
KW - Shared decision-making
UR - http://www.scopus.com/inward/record.url?scp=85165429430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165429430&partnerID=8YFLogxK
U2 - 10.1007/s13555-023-00948-6
DO - 10.1007/s13555-023-00948-6
M3 - Review article
AN - SCOPUS:85165429430
SN - 2193-8210
VL - 13
SP - 1893
EP - 1907
JO - Dermatology and Therapy
JF - Dermatology and Therapy
IS - 9
ER -